Compare JOE & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | APGE |
|---|---|---|
| Founded | 1936 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.7B |
| IPO Year | 2002 | 2023 |
| Metric | JOE | APGE |
|---|---|---|
| Price | $61.88 | $80.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $109.67 |
| AVG Volume (30 Days) | 165.3K | ★ 577.3K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 56.69 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $513,246,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $271.94 | ★ N/A |
| Revenue Growth | ★ 27.44 | N/A |
| 52 Week Low | $43.17 | $34.34 |
| 52 Week High | $73.54 | $95.32 |
| Indicator | JOE | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 43.75 |
| Support Level | $58.93 | $73.06 |
| Resistance Level | $62.29 | $84.56 |
| Average True Range (ATR) | 2.29 | 3.49 |
| MACD | -0.47 | -1.46 |
| Stochastic Oscillator | 9.83 | 3.74 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.